BioNexus Gene Lab Corp. (BGLC)

NASDAQ: BGLC · Real-Time Price · USD

1.370

-0.140 (-9.27%)

At close: Jul 27, 2026, 4:00 PM EDT

1.360

-0.010 (-0.73%)

After-hours: Jul 27, 2026, 4:20 PM EDT

BioNexus Gene Lab Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-2.9	-2.98	-1.6	-2.63	-0.36
Depreciation & Amortization	0.17	0.17	0.15	0.11	0.11
Stock-Based Compensation	-	0.79	0.14	-	-
Other Adjustments	0.3	0.17	-0.9	0.58	-0.03
Change in Receivables	1.14	0.78	0.15	0.65	0.54
Changes in Inventories	0.51	0.71	-0.25	-0.16	0.54
Changes in Accounts Payable	-0.88	-1.38	0.2	-0.38	-0.12
Changes in Unearned Revenue	-0.01	-0.09	0.1	-0.02	-0.08
Changes in Other Operating Activities	-0.26	-0.01	-0.08	0.03	-0.05
Operating Cash Flow	-1.16	-1.84	-2.09	-1.82	0.55
Operating Cash Flow Growth	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Capital Expenditures	-0.03	-0.04	-0.23	-0.15	-0.05
Purchases of Investments	-	-0.01	-0.49	-0.32	-0.51
Proceeds from Sale of Investments	-	1.03	1.07	0.03	-
Other Investing Activities	-0.05	-0.04	0.07	-1.35	0.12
Investing Cash Flow	0.95	0.94	0.42	-1.79	-0.45

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Issuance of Common Stock	-	0.27	-	6.26	0.15
Net Common Stock Issued (Repurchased)	-	0.27	-	6.26	0.15
Other Financing Activities	0.09	0.03	0	0.01	-0.04
Financing Cash Flow	0.36	0.3	0	6.27	0.11

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Foreign Exchange Rate Adjustments	0.16	0.19	0.04	-0.26	-0.21
Net Cash Flow	0.31	-0.4	-1.63	2.4	-0.01

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-1.19	-1.88	-2.32	-1.97	0.5
Free Cash Flow Growth	-	-	-	-	-
FCF Margin	-22.41%	-25.26%	-24.40%	-20.18%	4.55%
Free Cash Flow Per Share	-0.59	-1.01	-1.30	-1.24	0.35
Levered Free Cash Flow	-3.4	-3.62	-1.7	-3.2	-0.01
Unlevered Free Cash Flow	-3.38	-3.6	-1.68	-3.19	0

SEC Filings: 10-K · 10-Q